First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial

BACKGROUND: Extrapulmonary neuroendocrine carcinoma (EP-NEC) are an aggressive subgroup of neuroendocrine neoplasms (NEN). Advanced EP-NEC is generally treated with platinum-based cytotoxic regimens, but progressive disease occurs rapidly, resulting in a poor prognosis. Genetic alterations in the ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Levy, Sonja, Verbeek, Wieke H.M., Eskens, Ferry A.L.M., van den Berg, José G., de Groot, Derk Jan A., van Leerdam, Monique E., Tesselaar, Margot E.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891910/
https://www.ncbi.nlm.nih.gov/pubmed/35251315
http://dx.doi.org/10.1177/17588359221077088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891910/
https://www.ncbi.nlm.nih.gov/pubmed/35251315
http://dx.doi.org/10.1177/17588359221077088

Ejemplares similares